Results 81 to 90 of about 19,806 (216)
VIEW, EarlyView.Comprehensive evaluation of metagenomic next‐generation sequencing for pathogen identification in patients with suspected infection: Establishment of a standardized validation workflow. Abstract Metagenomic next‐generation sequencing (mNGS) enables unbiased identification of pathogens directly from clinical specimens. Despite its growing application in
Wen Shu +11 more
wiley +1 more source
Assessment of cfDNA Levels in Saliva Samples of Stressed Young Adults: Preliminary Study
Ahi Evran Medical JournalPurpose: The aim of this pilot study was to examine the levels of cell-free DNA (cfDNA) in the saliva samples of second-year medical students before and after a stress-inducing event, exams. Materials and Methods: Saliva samples were collected from 20
Ekin Çelik +6 more
doaj +1 more source
Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients
Kidney Research and Clinical Practice, 2015 Background: The plasma levels of cell-free DNA (cfDNA) are known to be elevated under inflammatory or apoptotic conditions. Increased cfDNA levels have been reported in hemodialysis (HD) patients.
Da Wun Jeong +9 more
doaj +1 more source
Andrology, EarlyView.ABSTRACT Background Despite robust data showing strong potential to improve diagnosis and disease monitoring in testicular germ cell tumors (TGCTs), miR‐371a‐3p testing has not yet been implemented in routine clinical practice. Cell‐free DNA (cfDNA) represents another promising liquid biopsy biomarker that may provide complementary molecular ...
Laura Matouskova +6 more
wiley +1 more source
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.Fetuses with a nuchal translucency between 3.0 and 3.4 mm showed a high rate of chromosomal anomalies and copy number variants, most of which could potentially be detected through cell‐free DNA. Abstract Introduction To report the prevalence of chromosomal anomalies in fetuses with a nuchal translucency (NT) between 3.0 and 3.4 mm and to assess the ...
Arianna Carta +10 more
wiley +1 more source
Акушерство, гинекология и репродукцияIntroduction. Currently, non-invasive prenatal testing (NIPT) is widely used to assess a risk of fetal chromosomal anomalies. NIPТ accuracy depends on the cell-free fetal DNA (cffDNA) percentage relative to total cell-free DNA in the pregnant woman's ...
E. S. Vashukova +6 more
doaj +1 more source
A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial
British Journal of Haematology, EarlyView.The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne +28 more
wiley +1 more source
Cancer Science, EarlyView.In patients with esophageal squamous cell carcinoma receiving definitive radiotherapy combined with systemic therapy, posttreatment TP53 mutation clearance and ctDNA‐MRD negativity predict favorable outcomes, whereas persistent ctDNA signals indicate elevated relapse risk, supporting nucleosome‐ and MRD‐informed surveillance and risk‐stratification ...
Shutang Liu +9 more
wiley +1 more source
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Several benign, inflammatory and malignant lesions can present as iris or anterior chamber masses, including iris naevi, cysts, adenomas, leiomyomas, nodules, vascular tumours, melanomas, metastases, as well as iris and pigment epithelium adenocarcinomas. Fortunately, benign iris lesions are much more common than malignant tumours and many can
Charles N. J. McGhee +3 more
wiley +1 more source
Liquid Biopsy and Multi‐Cancer Early Detection Tests for Cancer Screening: A Scoping Review
Clinical Genetics, EarlyView.There is a large body of evidence on liquid biopsy and multi‐cancer detection tests for cancer screening. Most studies addressed test performance outcomes, while fewer addressed clinical outcomes, implementation, and cost‐effectiveness. No studies evaluated cancer mortality.
Tessa Robinson +6 more
wiley +1 more source